Edition:
United Kingdom

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,680.00GBp
23 May 2017
Change (% chg)

-- (--)
Prev Close
1,680.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
815,858
52-wk High
2,703.00
52-wk Low
1,573.00

HIK.L

Chart for HIK.L

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products... (more)

Overall

Beta: 1.18
Market Cap(Mil.): £4,660.57
Shares Outstanding(Mil.): 239.98
Dividend: 18.00
Yield (%): --

Financials

  HIK.L Industry Sector
P/E (TTM): 37.88 29.41 30.38
EPS (TTM): 0.51 -- --
ROI: 5.83 13.85 13.36
ROE: 8.30 14.79 14.50

Hikma cuts revenue forecast on generic Advair delay; shares sink

Hikma Pharmaceuticals Plc lowered its full-year revenue forecast on Friday to reflect a delay in the launch of its generic asthma drug amid pricing pressures in the United States, sending its shares down to a three-year low.

19 May 2017

UPDATE 2-Hikma cuts revenue forecast on generic Advair delay; shares sink

May 19 Hikma Pharmaceuticals Plc lowered its full-year revenue forecast on Friday to reflect a delay in the launch of its generic asthma drug amid pricing pressures in the United States, sending its shares down to a three-year low.

19 May 2017

Hikma trims full year revenue forecast on Advair U.S. launch delay

Drugmaker Hikma Pharmaceuticals Plc on Friday lowered its revenue forecast for the full year to reflect a delay in the launch of its generic asthma drug, after U.S. regulators denied approval citing "major" issues with the application.

19 May 2017

BRIEF-Hikma sees FY group revenue between $2.0-$2.1 bln at constant currency

* Expect full year group revenue to be in range of $2.0-$2.1 billion in constant currency in 2017

19 May 2017

Hikma's generic Advair faces U.S. delay, 2017 approval unlikely

LONDON, May 11 Hikma Pharmaceuticals said on Thursday that U.S. regulators had decided not to approve its generic copy of GlaxoSmithKline's blockbuster lung drug Advair at this time, due to 'major' issues with its application.

11 May 2017

RPT-BRIEF-Hikma enters into settlement agreement with Jazz

* Enters into settlement agreement with Jazz for sodium oxybate

06 Apr 2017

BRIEF-Hikma enters into settlement agreement with Jazz

* Enters into settlement agreement with Jazz for sodium oxybate

06 Apr 2017

BRIEF-Jazz Pharma settles Xyrem patent litigation with Hikma Pharma

* Jazz Pharmaceuticals reaches settlement with Hikma Pharmaceuticals related to Xyrem patent litigation

05 Apr 2017

BRIEF-Hikma sees 2017 revenue to be around $2.2 bln

* FY group revenue of $1,950 million, up 35% and up 39% in constant currency

15 Mar 2017

BRIEF-Hikma signs licensing deal with Orion for asthma product

* Signed an exclusive licensing and distribution agreement with Orion Corporation Of Finland, for its new Easyhaler combination product

13 Feb 2017

More From Around the Web

Earnings vs. Estimates